SCHEMBL15548780

SCHEMBL15548780

Cn1ccc2cc(Cl)ncc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 1/20 0.62
MAPT P10636 2/20 0.50
PRKCI P41743 1/20 0.44
CYP2A6 P11509 2/20 0.41
GRM4 Q14833 1/20 0.39
CDC7 O00311 1/20 0.39
CDK2 P24941 1/20 0.39
CYP19A1 P11511 1/20 0.38
HSD11B1 P28845 1/20 0.37
EGFR P00533 2/20 0.36
LRRK2 Q5S007 1/20 0.36
MAOB P27338 1/20 0.35
CCR9 P51686 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633547 1.00 PIK3CB (0.62) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL18230343 0.85 CDC7 (0.49) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL31435644 0.85 CDC7 (0.49) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL7914260 0.78 PIK3CB (0.65) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL31036072 0.77 PIK3CB (1.00) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL17336491 0.77 PIK3CB (0.62) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL3481247 0.77 PIK3CB (1.00) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL30202304 0.77 PIK3CB (0.62) PIK3CBMAPTPRKCICYP2A6GRM4
SCHEMBL24824868 0.77 PIK3CB (0.38) PIK3CBMAPTCDC7CDK2CCR9
SCHEMBL2226803 0.77 PIK3CB (0.38) PIK3CBMAPTCDC7CDK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082069-A1 COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN 中国海洋大学 2025-04-24 WO disclosed
CN-117043162-A TYK2 selective inhibitors and uses thereof 迈巴制药(南京)有限公司 2023-11-10 CN disclosed
WO-2022076975-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
EP-2855477-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS Merck Sharp & Dohme Corp. (US) 2015-04-08 EP disclosed
WO-2013181075-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MAPT, SLC14A1, UBTF PIK3CB 2079/4885MAPT 1/4885PRKCI 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.